Intensifying or simplifying your bioprocess can mean more product, shorter manufacturing times, or lower costs –understanding what matters most is key to making the right decisions.
Many pharma companies struggle to strike the right balance between enough preventative maintenance and not too much corrective maintenance for manufacturing equipment, and to achieve that balance at a reasonable cost. One method known to drive the preventative/corrective ratio in favor of preventative maintenance is centerlining.
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Two industry experts detail strategies to meet supply chain challenges.
Mergers and acquisitions have come to define both growth and consolidation in pharmaceutical manufacturing over the last decade. Often, a merger or acquisition is the quickest, most cost-effective way to realize advanced capability without building a facility from the ground up. Buying specific capacity that either is lacking or will bolster a company’s overall offering generally makes more sense for both budgets and bottom lines — especially when dealing with an undervalued company. However, even a successful merger or acquisition of manufacturing facilities creates a range of asset management issues, including determining the fate of redundant operations and equipment.
Choosing the right contract organization to handle the development and manufacturing of a drug product is of critical importance. Here are tips to ensure a successful outcome.
Whether your goal is to increase patient compliance, improve clinical outcomes, or to extend a product’s lifecycle, modified-release dosage forms present a solution to myriad challenges.
Though the timelines may vary, across the globe more and more countries are requiring product identifiers and serialization of prescription drugs — right down to individual salable units.
Bilayer is considerably more convenient for patients due to receive multiple medications or longer-lasting profiles in a single dosage form and has the added benefit of improved patient compliance. This Q&A explores the manufacturing challenges, how to overcome them and considerations when selecting a CDMO for the manufacturing process.
Thist article disucsses two trends turning the flowmeter industry on its ear: advances in flowmeter diagnostics and the adoption of smartphone-like technology to improve access and communications.
Done correctly, Process Characterization reduces the risk of manufacturing failures and regulatory delays. Scientists at the AbbVie Bioresearch Center (ABC) have established a platform approach to Process Characterization that has been proven effective as it has been used to support the approval of several marketed products.
|
|
|
|
|
|
|
|
|